📊 XENE Key Takeaways
Is Xenon Pharmaceuticals Inc. (XENE) a Good Investment?
Xenon Pharmaceuticals is a pre-revenue stage biotech burning $279M annually with only $7.5M in revenue and $199.2M in remaining cash—providing less than one year of runway at current burn rates. Despite a strong balance sheet and excellent liquidity ratios, the company faces critical execution risk with no visible path to profitability and an unsustainable cash depletion trajectory absent major clinical wins, partnerships, or capital raises.
Why Buy Xenon Pharmaceuticals Inc. Stock? XENE Key Strengths
- Strong balance sheet with $581.8M stockholders equity providing financial cushion
- Excellent liquidity position with 13.42x current ratio and minimal debt burden (Debt/Equity 0.02x)
- Low leverage with only $10.9M long-term debt reduces financial distress risk in near term
XENE Stock Risks: Xenon Pharmaceuticals Inc. Investment Risks
- Catastrophic cash burn of $279.1M annually with only $199.2M cash reserves indicating less than one year of operational runway
- Minimal revenue generation of $7.5M indicates no commercialized products and heavy dependency on R&D pipeline success
- Negative operating cash flow and massive operating loss of -$373.1M suggest company is entirely in pre-commercial development phase with high probability of required dilutive financing or failure
- Negative profitability metrics (operating margin -4974%, net margin -4612%) are structurally unsustainable
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining until depletion
- Clinical trial progress and regulatory milestones for pipeline assets
- Revenue growth trajectory and achievement of first commercial product sales
- Financing announcements and capital raise activities
- Operating expense reduction initiatives and burn rate management
Xenon Pharmaceuticals Inc. (XENE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.42x current ratio provides a solid financial cushion.
XENE Profit Margin, ROE & Profitability Analysis
XENE vs Healthcare Sector: How Xenon Pharmaceuticals Inc. Compares
How Xenon Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xenon Pharmaceuticals Inc. Stock Overvalued? XENE Valuation Analysis 2026
Based on fundamental analysis, Xenon Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xenon Pharmaceuticals Inc. Balance Sheet: XENE Debt, Cash & Liquidity
XENE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xenon Pharmaceuticals Inc.'s revenue has declined by 77% over the 5-year period, indicating business contraction. The most recent EPS of $-2.73 indicates the company is currently unprofitable.
XENE Revenue Growth, EPS Growth & YoY Performance
XENE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$47.9M | $-0.81 |
| Q2 2025 | N/A | -$47.9M | $-0.75 |
| Q1 2025 | N/A | -$47.9M | $-0.62 |
| Q3 2023 | $132.0K | -$19.7M | $-0.57 |
| Q2 2023 | $536.0K | -$19.7M | $-0.55 |
| Q1 2023 | $8.8M | -$19.7M | $-0.35 |
| Q3 2022 | $132.0K | -$15.4M | $-0.36 |
| Q2 2022 | $536.0K | -$15.8M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xenon Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
XENE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xenon Pharmaceuticals Inc. (CIK: 0001582313)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XENE
What is the AI rating for XENE?
Xenon Pharmaceuticals Inc. (XENE) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XENE's key strengths?
Claude: Strong balance sheet with $581.8M stockholders equity providing financial cushion. Excellent liquidity position with 13.42x current ratio and minimal debt burden (Debt/Equity 0.02x).
What are the risks of investing in XENE?
Claude: Catastrophic cash burn of $279.1M annually with only $199.2M cash reserves indicating less than one year of operational runway. Minimal revenue generation of $7.5M indicates no commercialized products and heavy dependency on R&D pipeline success.
What is XENE's revenue and growth?
Xenon Pharmaceuticals Inc. reported revenue of $7.5M.
Does XENE pay dividends?
Xenon Pharmaceuticals Inc. does not currently pay dividends.
Where can I find XENE SEC filings?
Official SEC filings for Xenon Pharmaceuticals Inc. (CIK: 0001582313) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XENE's EPS?
Xenon Pharmaceuticals Inc. has a diluted EPS of $-4.36.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XENE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Xenon Pharmaceuticals Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XENE stock overvalued or undervalued?
Valuation metrics for XENE: ROE of -59.5% (sector avg: 15%), net margin of -4,612.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XENE stock in 2026?
Our dual AI analysis gives Xenon Pharmaceuticals Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XENE's free cash flow?
Xenon Pharmaceuticals Inc.'s operating cash flow is $-279.1M, with capital expenditures of $799.0K. FCF margin is -3,732.2%.
How does XENE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,612.1% (avg: 12%), ROE -59.5% (avg: 15%), current ratio 13.42 (avg: 2).